MiNK Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
MiNK Therapeutics, Inc. (INKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $12.97 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $12.97.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $6.90, a 296.55% increase year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.74, a 19.07% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $2.15.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $10.04, a 46.36% increase from fiscal 2024.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $6.86, a 61.46% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $17.80, a 709.09% increase from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.20, a 25.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.97 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | $12.97 10-Q · filed 2026-05-15 | |||||||
| 2025-12-31 | $10.04 10-K · filed 2026-03-31 | |||||||
| 2025-09-30 | $5.92 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | $5.92 10-Q · filed 2026-08-13 | |||||||
| 2024-12-31 | $6.86 10-K · filed 2026-03-31 | |||||||
| 2024-09-30 | $6.90 10-Q · filed 2025-11-14 | $0.69 10-Q · filed 2024-11-14 | ||||||
| 2024-06-30 | $6.90 10-Q · filed 2025-08-14 | $0.69 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | $6.90 10-Q · filed 2025-05-15 | $0.69 10-Q · filed 2024-05-14 | ||||||
| 2023-12-31 | $17.80 10-K · filed 2025-03-18 | $1.78 10-K · filed 2024-03-21 | ||||||
| 2023-09-30 | $1.79 10-Q · filed 2024-11-14 | |||||||
| 2023-06-30 | $1.70 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | $1.74 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | $2.20 10-K · filed 2024-03-21 | |||||||
| 2022-09-30 | $2.15 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | $2.15 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $2.15 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $1.76 10-K · filed 2023-03-24 | |||||||
| 2021-09-30 | $1.76 10-Q · filed 2021-11-29 | |||||||
| 2020-12-31 | $0.01 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |